Novo Nordisk A/S (CPH:NOVO.B)
237.35
-1.25 (-0.52%)
Feb 27, 2026, 2:21 PM CET
Novo Nordisk Revenue
In the year 2025, Novo Nordisk had annual revenue of 309.06B DKK with 6.43% growth. Novo Nordisk had revenue of 79.14B in the quarter ending December 31, 2025, a decrease of -7.63%.
Revenue
309.06B
Revenue Growth
+6.43%
P/S Ratio
3.43
Revenue / Employee
4.47M
Employees
69,505
Market Cap
1.06T
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 309.06B | 18.66B | 6.43% |
| Dec 31, 2024 | 290.40B | 58.14B | 25.03% |
| Dec 31, 2023 | 232.26B | 55.31B | 31.26% |
| Dec 31, 2022 | 176.95B | 36.15B | 25.68% |
| Dec 31, 2021 | 140.80B | 13.85B | 10.91% |
| Dec 31, 2020 | 126.95B | 4.93B | 4.04% |
| Dec 31, 2019 | 122.02B | 10.19B | 9.11% |
| Dec 31, 2018 | 111.83B | 135.00M | 0.12% |
| Dec 31, 2017 | 111.70B | -84.00M | -0.08% |
| Dec 31, 2016 | 111.78B | 3.85B | 3.57% |
| Dec 31, 2015 | 107.93B | 19.12B | 21.53% |
| Dec 31, 2014 | 88.81B | 5.23B | 6.26% |
| Dec 31, 2013 | 83.57B | 5.55B | 7.11% |
| Dec 31, 2012 | 78.03B | 11.68B | 17.60% |
| Dec 31, 2011 | 66.35B | 5.57B | 9.16% |
| Dec 31, 2010 | 60.78B | 9.70B | 18.99% |
| Dec 31, 2009 | 51.08B | 5.53B | 12.13% |
| Dec 31, 2008 | 45.55B | 3.72B | 8.90% |
| Dec 31, 2007 | 41.83B | 3.09B | 7.97% |
| Dec 31, 2006 | 38.74B | 4.98B | 14.76% |
| Dec 31, 2005 | 33.76B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Coloplast | 27.89B |
| H. Lundbeck | 24.63B |
| Genmab | 23.66B |
| Demant | 22.97B |
| GN Store Nord | 16.78B |
| Zealand Pharma | 9.21B |
| Bavarian Nordic | 6.89B |
| ALK-Abelló | 6.31B |
Novo Nordisk News
- 1 hour ago - Why I'm Still Bullish On Novo Nordisk Despite Recent Setbacks - Seeking Alpha
- 15 hours ago - Forget Altimmune: This Proven Obesity‑Drug Giant Is the Better Weight‑Loss Play - The Motley Fool
- 16 hours ago - Why Shares of Novo Nordisk Stock Sank (Again) This Week - The Motley Fool
- 17 hours ago - INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novo Nordisk A/S - NVO - PRNewsWire
- 1 day ago - Novo Nordisk: Can't Ignore It At These Valuations (Rating Upgrade) - Seeking Alpha
- 1 day ago - Stock Market Today, Feb. 25: Novo Nordisk Dips After Announcing $2.1 Billion Partnership With Vivtex for Oral Drug-Delivery Technologies - The Motley Fool
- 1 day ago - 1 Reason Why I'd Hold This Weight‑Loss Drug Leader Through Any Market Crash - The Motley Fool
- 1 day ago - Novo Nordisk's 40% Fall May Be Creating A Deep-Value Moment - Benzinga